PPIDT00278

Drug Information
NameAntihemophilic factor (recombinant), PEGylated
SequenceNot Available
DrugBank_IDDB09329
Typebiotech
IndicationFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064]. This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].

Dosage Forms
Form Route Strength
Kit; powder, for solution Intravenous
1000 unit / vial
Kit; powder, for solution Intravenous
1500 unit / vial
Kit; powder, for solution Intravenous
2000 unit / vial
Kit; powder, for solution Intravenous
250 unit / vial
Kit; powder, for solution Intravenous
3000 unit / vial
Kit; powder, for solution Intravenous
500 unit / vial
Kit; powder, for solution Intravenous
750 unit / vial
Injection, powder, lyophilized, for solution Intravenous
1000 IU
Injection, powder, lyophilized, for solution Intravenous
1500 IU
Injection, powder, lyophilized, for solution Intravenous
2000 IU
Injection, powder, lyophilized, for solution Intravenous
3000 IU
Injection, powder, lyophilized, for solution Intravenous
500 IU
Injection, powder, lyophilized, for solution Intravenous
50000000 IU
Injection, powder, lyophilized, for solution Intravenous
100000000 IU
Injection, powder, lyophilized, for solution Intravenous
200000000 IU
Injection, powder, lyophilized, for solution Intravenous
250 IU
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P04275 VWF von Willebrand factor Homo sapiens binder Link
carrier P04275 VWF von Willebrand factor Homo sapiens unknown Link